公司資料
Innate Pharma 股價、新聞與催化劑
- 股票代碼:
- IPHA
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- France
股票表現
2.26 USD (+8.13%)
收盤價
最後更新: 2026年8月21日
171M USD
市值
股價為何變動
As of Aug 21, 2026, IPHA closed up 8.13% at $2.26. No new same-company headline was identified in the current news window.
公司概覽
Innate Immunity Oncology Company
Innate Pharma develops antibodies and antibody-drug conjugates that engage innate and adaptive immunity against cancer.
Lacutamab
Lacutamab targets KIR3DL2 and is being developed for cutaneous T-cell lymphoma.
ADC and Partnered Pipeline
IPH4502 is a Nectin-4 ADC, while partnered programs include monalizumab and anti-CD39 antibody IPH5201 with AstraZeneca.
未來催化劑
- Initiation of the confirmatory Phase 3 TELLOMAK-3 study of lacutamab is planned for the second half of 2026, subject to securing non-dilutive financing.
- Phase 3 PACIFIC-9 data for the monalizumab-containing regimen are planned for the second half of 2026.
近期新聞
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。